Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: Assessment and implications for epidemiology

American Journal of Epidemiology

Volumn 149, Issue 3, 1999, Pages 261-267

  Sakkinen, Pamela A ^a   Macy, Elizabeth M ^a   Callas, Peter W ^b   Cornell, Elaine S ^a   Hayes, Timothy E ^c   Kuller, Lewis H ^d   Tracy, Russell P ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b University of Vermont   (United States)

^c MAINE MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cardiovascular disease; Hemostasis; Variability

Indexed keywords

ADULT; AGED; ARTICLE; BIOASSAY; BLOOD CHEMISTRY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EPIDEMIOLOGICAL DATA; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INFLAMMATION; MALE; NORMAL HUMAN; OBSERVER VARIATION; RISK FACTOR;

EID: 0033081314     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a009801     Document Type: Article

References (30)

1. Fuster V, Badimon L, Badimon J, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes: part 1. N Engl J Med 1992;326:242-50.
2. Fuster V, Badimon L, Badimon J, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes: part 2. N Engl J Med 1992;326:310-18.
3. Kleinbaiun D, Kupper L, Morganstern H. Epidemiologic research. Belmont, CA: Lifetime Learning Publications, 1982.
4. Phillips A, Smith G. How independent are "independent" effects? Relative risk estimation when correlated exposures are measured imprecisely. J Clin Epidemiol 1991;44:1223-31.
5. Greenland S. The effect of misclassification in the presence of covariates. Am J Epidemiol 1980;112:564-9.
6. Kupper L. Effects of the use of unreliable surrogate variables on the validity of epidemiologic research studies. Am J Epidemiol 1984;120:643-8.
7. Fuller W. Measurement for error models. New York: John Wiley & Sons, 1987.
8. Thompson S, Martin J, Meade T. Sources of variability in coagulation factor assays. Thromb Haemost 1987;58:1073-7.
9. de Maat M, de Bart A, Hennis B, et al. Interindividual and intraindividual variability in plasma fibrinogen, t-PA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol 1996;16:1156-62.
10. Rosenson R, Tangney C, Hafner J. Intraindividual variability of fibrinogen levels and cardiovascular risk profile. Arterioscler Thromb 1994;14:1928-32.
11. Nguyen N, Ghaddar H, Stinson V, et al. ARIC hemostasis study - IV. Intraindividual variability and reliability of hemostatic factors. Thromb Haemost 1995;73:256-60.
12. Chambless L, McMahon R, Brown S, et al. Short-term intra-individual variability in lipoprotein measurements: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 1992;136:1069-81.
13. Macy E, Meilahn E, Declerck P, et al. Sample preparation for plasma measurement of plasminogen activator inhibitor-1 antigen in large population studies. Arch Path Lab Med 1993; 117:67-70.
14. DeClerck P, Alessi M, Verstreken M, et al. Measurement of plasminogen activator inhibitor 1 (PAI-1) in biological fluids with a murine monoclonal antibody based enzyme-linked immunosorbent assay. Blood 1988;71:220-5.
15. Tracy R, Bovill E. Plasminogen and alpha-2-antiplasmin. In: Williams hematology. Beutler E, Lichtman M, Coller B, et al, eds. New York: McGraw-Hill, 1995:L106-L107.
16. Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemostas 1985;54: 684-97.
17. Declerck P, Verstrecken M, Collen D. Measurement of different forms of plasminogen activator inhibitor 1 (PAI-1) using various monoclonal antibody-based enzyme-linked immunosorbent assays. Fibrinolysis 1990;4:132-3.
18. Holvoet P, de Boer A, Verstreken M, et al. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-alpha-2-antiplasmin complex in human plasma-application to the detection of in vivo activation of the fibrinolytic system. Thromb Haemostast 1986;56:124-7.
19. Declerck P, Mombaerts P, Holvoet R, et al. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis. Thromb Haemostast 1987;58:1024-9.
20. Tracy R, Jenny R, Williams B, et al. Active site-specific assays for enzymes of the coagulation and fibrinolytic pathways. In: Methods of enzymology. Lorand L, Mann K, eds. San Diego. CA: Academic Press, 1993:514-24.
21. Tracy R , Bovill E. Methods for determining fibrinopeptide A. In: Beutler E, Lichtman M, Coller B, et al, eds. Williams hematology. New York: McGraw-Hill, 1995:L96-L97.
22. Macy E, Hayes T, Tracy R. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference interval and epidemiological applications. Clin Chem 1997;43:52-8.
23. Clauss A. Gerinnungs-physiologische schnell-methode zur bestimmung des fibrinogens. Acta Haematol 1957;17: 237-46.
24. Geffken D, Keating F, Kennedy M, et al. The measurement of fibrinogen in population-based research: studies on instrumentation and methodology. Arch Pathol Lab Med 1994; 118:1106-9.
25. Cushman M, Cornell E, Howard P, et al. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 1995;41:264-70.
26. Fraser C, Harris E. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409-37.
27. Searle S. Linear models. New York: John Wiley & Sons, 1971.
28. Cochran W. The distribution of the largest of a set of estimated variances as a traction of their total. Ann Eugen 1941;11:47.
29. Liu K, Stamler J, Dyer A, et al. Statistical methods to assess and minimize the role of intra-individual variability in obscuring the relationship between dietary lipids and serum cholesterol. J Chronic Dis 1978;31:397-412.
30. SPSS/PC+ V2.0. Chicago. IL: SPSS Inc. 1988.